This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech Stock Mailbag: Exact Sciences, Rexahn, Advaxis, Peregrine

Robert K. asks, "Adam, how does something like Rexahn Pharmaceuticals (RNN) happen?"

Ha! I take it you mean, how does a company with a long history of drug development failure, abandoned by investors, somehow resurrect itself and become one of this year's top stock performers?

Rexahn "happens" because the biotech stock bubble has an amnestic effect on a lot of investors. They buy what they think is a shiny new stock, when in fact, it's just a throwaway vamped up with new paint.

Take Rexahn's lead cancer drug Archexin. In January, the company announced the start of a phase II study in patients with advanced kidney cancer.

Um... Rexahn tried this before unsuccessfully. A phase II study of Archexin in kidney cancer was abandoned in 2009:

From Rexahn's 2009 10-K:

Archexin is currently in Phase II clinical trials for the treatment of pancreatic cancer with patient enrollment underway. Archexin's Phase II clinical trial protocol for the treatment of renal cell carcinoma (RCC) was accepted by the FDA, but issues with enrollment have delayed the trial. Such enrollment issues were primarily due to the fact that there is a small number of patients that have been diagnosed with RCC and such patients are often treated with surgery instead of drug therapies. After further consideration of the trial design and the limited number of patients, there was a reallocation of resources and Rexahn reprioritized Archexin to pursue studies in pancreatic cancer and ovarian cancer.

Mediocre (and frankly, unreliable) results from that phase II study of Archexin in pancreatic cancer were released in August 2012. Last September, Rexahn admitted Rexahn's development path in pancreatic cancer was futile

Sell-side analysts like H.C Wainwright's Andrew Fein are telling investors to buy Rexahn today with nary a mention of Archexin's troubled history. Surprise, surprise.

Rexahn and its enablers like Fein are also playing selective disclosure with a second cancer drug candidate. "Management indicated that RX-3117 partnership discussions have been ongoing and are confident of a deal by mid-2014," Fein wrote in a January research note.

Left unsaid: Rexahn had a partner for RX-3117. Teva (TEVA) signed on to fund early development of the drug in 2009. Last August, Teva gave the drug back to Rexahn.

2 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG
ADXS $17.07 0.00%
EXAS $22.02 0.00%
PPHM $1.31 0.00%
RNN $0.72 0.00%
AAPL $128.95 0.00%

Markets

DOW 18,024.06 +183.54 1.03%
S&P 500 2,108.29 +22.78 1.09%
NASDAQ 5,005.3910 +63.9670 1.29%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs